Dendritic cells (DCs) are potent antigenpresenting cells with key roles in the initiation and regulation of immune responses. [1] [2] [3] In the respiratory tract, they constantly sample inhaled antigens from the airway and alveolar epithelial surfaces, before migrating to regional lymph nodes where they present processed peptides to antigenspecific T cells. DC are unique in their capacity to activate naïve T cells and initiate primary immune responses in lymph nodes, and also play a central role in reactivating memory T-cell responses in the lungs. However, DC are far more than a passive conduit for delivering antigens to lymph node T cells. They are exquisitely sensitive to environmental signals be they derived from microbes, allergens, pollutants, or the products of tissue damage. DCs are responsive to pathogen-associated molecular patterns and damage-associated molecular patterns, and this markedly alters the signals they provide to T cells. Similarly, airborne pollutants such as diesel exhaust particles can alter DC function directly, 4 or via interactions with airway epithelial cells. 5 DCderived signals regulate both the degree of T-cell activation and the nature or flavor of the immune response (eg, T helper (Th) 1, Th2, Th17, B-cell help) or immune regulation (Fig 1) . DCs can therefore be viewed as finely tuned mechanisms for integrating and transferring information from the lung to regional lymph nodes. In health, the ensuing immune response is appropriate to the type of pathogen and the presence or absence of tissue damage; however, this is often perturbed in various lung diseases. It is estimated that pDCs dedicate as much as 60% of their transcriptome to type I IFN production 8 and can release 100-fold more IFNa than any other known cell type. 9 Even though pDCs appear to be fully developed when they exit the bone marrow, they are relatively inefficient at presenting antigens to T cells and seem to play an important role in tolerance induction, 10 probably via induction of regulatory T cells. 11 In mice, pDC depletion induces a Th2 response and immunopathology after respiratory syncytial virus infection, 12 whereas our own studies have shown that pDCs from healthy people inhibit Th2 responses induced by rhinoviruses. 13 This regulatory mechanism may be lost in asthma. In humans, pDCs are identified by surface markers such as CD303 (a C-type lectin), CD304 or neuropilin-1, Ig-like transcript 7, and IL-3 receptor-a chain. journal.publications.chestnet.org known for some time that increased numbers of airway mucosal DCs are present in asthma. Initial studies used endobronchial biopsies and BAL, but it is now clear that airway DCs can also be identified and characterized with induced sputum from adults 14, 15 and children. 16 In fatal asthma there is a higher density of DCs in the outer wall of the large airways than in control subjects who died of nonpulmonary causes. 17 These
DC
DCs express factor XIIIa and are likely to have differentiated from recruited monocytes. 17 In people with allergic asthma, allergen inhalation has proved an effective method for studying the dynamics of DC migration because it induces increased numbers of sputum cDCs, including both CD11cþ and CD141þ subsets. 14, 18 Allergen challenge also increases the numbers of bone marrow cDCs, upregulating thymic stromal lymphopoietin (TSLP) receptor but not IL-33 receptor on bone marrow DCs, and primes bone marrow progenitors to differentiate into DCs in response to hematopoietic growth factors. 19 Studies in experimental asthma models have shown that airwayderived prostaglandins can exert long-lived immunomodulatory effects on DC progenitors in bone marrow 20 ; however, whether this also occurs in persistent human asthma has yet to be determined.
In asthma, airway cDCs express ligands and receptors involved in type 2 inflammation. Therefore, sputum cDCs from people with mild asthma show higher expression of the Th2, promoting costimulatory molecule OX40L and the chemokine ligand 17, than sputum cDCs from healthy control subjects, in conjunction with TSLP and IL-33 expression in airway epithelial cells. 21 Allergen inhalation leads to higher IL-25 receptor (also known as IL-17RB) expression on sputum cDCs and pDCs. 22 The fact that the IL-25 receptor is also upregulated on blood cDCs and pDCs suggests that allergen inhalation may be enhancing IL-25 receptor expression in bone marrow. People with allergic asthma also have a higher proportion of TSLP receptorexpressing cDCs in the blood and bronchial mucosa and are more responsive to the Th2-promoting effects of TSLP than healthy control subjects. 23 In asthma, it is likely that TSLP, IL-33, and IL-25 production by airway epithelial cells conditions DCs so that type 2 immune responses are enhanced. Further work is needed to examine the relative importance of TSLP, IL-33, and IL-25 across different asthma phenotypes. Conversely, lowdose endotoxin exposure protects against experimental asthma via induction of A20 in epithelial cells and inhibition of DC recruitment and activation. 24 Airway epithelial cells from people with asthma show lower expression of A20 than healthy control subjects. 24 Therefore, it is likely that this effects DC function in human asthma; however, this has yet to be confirmed.
In Th2 high asthma, greater numbers of airway mucosal CD1cþ cDCs express high-affinity IgE receptor alpha chain than Th2 low asthma. 25 Froidure and colleagues 26 previously reported that persistent asthma symptoms after a period of allergen avoidance were associated with the extent to which cDCs were able to promote Th2 cytokine production by CD4 T cells. House dust mite allergen upregulates CD141 expression on monocytederived DCs. 27 This is significant because CD141-expressing DCs induce a strongly Th2-polarized cytokine response in naïve 28 and memory CD4 T cells, 27 whereas CD141 expression in blood leukocytes is elevated during acute asthma exacerbations. 27 With respect to pDCs, a number of reports indicate that lung pDCs are recruited to the airway lumen after allergen inhalation, 14, 29 and this is associated with elevated numbers of bone marrow pDCs. 19 There is no consensus in the literature on whether circulating pDC numbers differ between adults with asthma and healthy individuals 30, 31 ; however, it is likely that pDCs fluctuate over time in response to environmental exposures, especially virus infections. In a birth cohort study, relative deficiency of circulating pDCs during infancy was shown to predict subsequent respiratory tract infections, wheezing, and diagnosis of asthma by the age of 5 years. 32 Asthma is also linked to changes in receptor expression and pDC function. After prolonged allergen avoidance, ongoing asthma symptoms are associated with persistently lower pDC expression of the ligand for the regulatory protein known as inducible costimulatory molecule. Blood mononuclear cells from those with asthma generally produce less IFNa after viral activation in vitro; this appears to be most evident in those with severe asthma 31, 33 and airway neutrophilia, 34 but it may not be seen in milder asthma. 35 Deficient IFN production by blood leukocytes in asthma is likely to be a consequence of pDC dysfunction; however, only a few studies have specifically examined purified pDCs. Gill and colleagues 36 demonstrated that influenza virusstimulated pDCs from people with asthma produce less IFNa than pDCs from healthy individuals, and this was amplified by IgE cross-linking. Similarly, in children with allergic asthma, high-affinity IgE receptor alpha chain expression on pDCs is inversely associated with rhinovirus-induced IFN-a and IFN-l1 production. 37 Furthermore, allergen inhalation enhances expression of granzyme B in airway pDCs. 38 
COPD
It is clear that cigarette smoking per se can lead to increases in the number of lung cDCs, even in the absence of overt lung disease. 39 These cDCs show prominent expression of the Langerhans cell markers langerin and CD1a and the costimulatory molecules CD80 and CD86. 39 The effects of cigarette smoke on DC production of IL-8 and prostaglandin E2 appear to be mediated via both oxidative stress and the direct effects of nicotine. 40 Lymphoid aggregates are a common feature in COPD, and these are often infiltrated by langerin-positive cDCs, especially in those with severe airflow obstruction. 41 Higher costimulatory molecule expression on lung cDCs has also been linked to disease severity. 42 The small airways in COPD contain cDCs with heightened expression of chemokine ligand 20, a potential cause of CD8 T-cell activation. 43 In contrast, there is evidence that some aspects of cDC function may be downregulated in COPD, with cDC immaturity associated with airway vascularity and expression of angiogenic factors 44 and reduced expression of the chemokine receptor CCR5. 45 Furthermore, a recent report indicates that CD1cþ DCs from patients with COPD hinder T-cell effector functions and favor the generation of suppressive T cells. The authors speculate that these features of cDCs might contribute to impaired immunity to respiratory viruses. 46 Although these observations may seem contradictory, they are consistent with the notion that COPD is characterized by a paradoxical combination of heightened inflammatory responses that contribute to tissue damage and reduced host defense against respiratory pathogens. There is a need for more research into the role that DC populations might play in disease progression and COPD exacerbations.
Microbes
There is considerable interest in the way that DCs respond to respiratory microbes, both pathogens and commensal organisms. Larsen and colleagues 47 recently compared the effects of airway commensals and pathogenic bacteria on human monocyte-derived DCs, reporting that pathogenic bacteria provoke considerably higher IL-23, IL-12p70, and IL-10 production than commensal bacteria, such as Prevotella species and Veillonella species. This may be a mechanism favoring clearance of pathogens from the lungs vs persistence of commensal organisms. In patients with acute pneumonia, blood mDC and pDC numbers are markedly reduced, relative to control subjects, probably as a result of their recruitment to inflamed lung tissue. 48 Expression of Fc-gamma receptors was elevated on mDCs, whereas toll-like receptor 9 was elevated on pDCs. 48 In a study of patients with 2009 influenza A(H1N1) hospitalized during the 2009 influenza pandemic, significant depletion of blood pDCs and mDCs was observed during the acute phase of the disease. 49 Interestingly, blood pDC counts remained persistently low for up to 16 weeks. 49 Lung Cancer and Mesothelioma
Most malignant tumors, including lung cancers and mesothelioma, can produce a variety of factors that suppress the generation of an efficient antitumor immune response as summarized recently. 50 Nonetheless, there is strong evidence that suggests that DC function in lung cancer has a major impact on clinical outcomes. In a study of 458 patients with primary lung carcinoma, a high density of mature DCs (ie, those highly expressing lysosomal-associated membrane protein-3) within tertiary lymphoid structures in tumors was significantly and independently associated with improved long-term survival. 51 Conversely, DCs isolated from non-small cell lung tumors can overexpress immunoregulatory molecules, such as programmed death-ligand 1 52 and CD276 (a member of the B7 family also known as B7-H3), 53 and these are likely to be associated with a poor prognosis. Lung cancers can secrete galectin-1 that enhances DC production of heparin-binding epidermal growth factorlike growth factor, which then increases cancer progression. 54 There is much interest in using DC-based vaccines in combination with activated killer T cells to enhance the host antitumor response in lung cancer. Although some early studies have shown promising results in patients with surgically resected non-small cell lung cancer, 55 confirmation in large multicenter studies is needed.
The Way Forward: Research and Potential Therapies
Even though many of the initial studies of human lung DCs relied on surgical resection specimens and lung biopsies, recent years have seen improved methods for identifying and characterizing DCs in the circulation, sputum, and BAL of patients with lung diseases. These journal.publications.chestnet.org relatively less invasive methods make serial measurements of DCs and longitudinal studies much more feasible. Much research on human DCs until now has involved small, cross-sectional observational studies. Although these have some value, there is a need for more sophisticated approaches that will allow us to better identify features of DC biology that predict important clinical outcomes and that might be therapeutic targets. Such approaches might involve experimental challenges with various environmental stimuli, dynamic studies of disease exacerbations, and large prospective studies of well-defined patient cohorts.
DCs have profound effects on cell-mediated and humoral immunity, and the future is likely to include new approaches whereby antigens or small molecules are targeted using antibodies to receptors on particular DC subpopulations. 56 This is likely to provide efficient mechanisms to enhance, suppress, or redirect immune responses against particular antigens while maintaining host defense and avoiding collateral lung tissue damage.
